NCT02580734.

Methods	Placebo‐controlled, triple‐blinded cross‐over RCT
Participants	20 BMS patients Mean age: Unknown until published (eligible age range 18 to 90) Sex: Distribution unknown until published Inclusion/exclusion and diagnostic criteria appropriate
Interventions	Intervention category: Dietary supplements Group 1: (n = 20) Melatonin 12 mg daily (3 mg capsules taken 4 times p/day) Group 2: (n = 20) Placebo (capsules taken 4 times p/day) Duration: 5 months (2 months, followed by 1 month washout, and then final 2 months)
Outcomes	Pain intensity at 2 months (assessed by VAS, verbal intensity score and numerical rating scale) QoL (assessed by SF‐36 (36‐Item Short Form Health Survey)) QoL surrogate: Anxiety (assessed by Hamilton Anxiety Rating Scale (HAM‐A)) Adverse effects Outcomes not of interest to this review Sleep (assessed by Epworth Sleepiness Scale (ESS) and sleep scale from the Medical Outcomes Study (MOS)) Serum melatonin levels (measured by blood sample)
Source of funding	Unknown until published
Notes	Study currently unpublished Contact: Andrea Sardella (andrea.sardella@unimi.it)